Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2007-08-07
2007-08-07
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S618000, C558S413000, C558S414000, C560S250000, C560S251000, C564S153000
Reexamination Certificate
active
10683157
ABSTRACT:
This invention provides a class of androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM). Several of the SARM compounds have been found to have an unexpected androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. Other SARM compounds have been found to have an unexpected antiandrogenic activity of a nonsteroidal ligand for the androgen receptor. The SARM compounds, either alone or as a composition, are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and/or prevention of acute and/or chronic muscular wasting conditions; e) preventing and/or treating dry eye conditions; f) oral androgen replacement therapy; g) decreasing the incidence of, halting or causing a regression of prostate cancer; and/or h) inducing apoptosis in a cancer cell.
REFERENCES:
patent: 3875229 (1975-04-01), Gold
patent: 4139638 (1979-02-01), Neri et al.
patent: 4191775 (1980-03-01), Glen
patent: 4239776 (1980-12-01), Glen et al.
patent: 4282218 (1981-08-01), Glen et al.
patent: 4386080 (1983-05-01), Crossley et al.
patent: 4465507 (1984-08-01), Konno et al.
patent: 4636505 (1987-01-01), Tucker
patent: 4880839 (1989-11-01), Tucker
patent: 5162504 (1992-11-01), Horoszewicz
patent: 5609849 (1997-03-01), Kung
patent: 5656651 (1997-08-01), Sovak et al.
patent: 6019957 (2000-02-01), Miller et al.
patent: 6071957 (2000-06-01), Miller et al.
patent: 6160011 (2000-12-01), Miller et al.
patent: 6492554 (2002-12-01), Dalton et al.
patent: 6569896 (2003-05-01), Dalton et al.
patent: 6995284 (2006-02-01), Dalton et al.
patent: 2001/0012839 (2001-08-01), Miller et al.
patent: 2004/0014975 (2004-01-01), Dalton et al.
patent: 2004/0029913 (2004-02-01), Dalton et al.
patent: 2004/0260092 (2004-12-01), Miller et al.
patent: 2005/0137172 (2005-06-01), Dalton et al.
patent: 0 040 932 (1981-02-01), None
patent: 0 100 172 (1984-02-01), None
patent: 00198352 (1989-01-01), None
patent: 0253 503 (1991-12-01), None
patent: 52128329 (0000-01-01), None
patent: WO 95/19770 (1995-07-01), None
patent: WO 98/53826 (1998-12-01), None
patent: WO 01/28990 (2001-04-01), None
patent: WO 2005/000794 (2005-01-01), None
Dukes, Steroids, vol. 65, pp. 725-731, 2000.
Chemical Abstracts 126:1283, abstract of Allan, Molecular Endocrinology, 10(10), 1206-1213, 1996.
Buchwald et al. “Long-tem, continuous intravenous heparin administration by an implantable infusion pump in ambulatory patients with recurrent venous thrombus”Surgery.
Doms et al. “HIV-1 Membrane Fusion: Targets of Opportunity”,The Journal of Cell Biology, vol. 151, No. 2, Oct. 2000 F9-F13.
Goodson et al. “Dental Applications”,Medical Applications of Controlled Release, vol. II, pp. 115-138, 1984.
Katre et al. “Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model”Proc. Natl. Acad. Sci. USA, vol. 84, pp. 1487-1491, 1987.
Langer Robert “New Methods of Drug Delivery”Sciencevol. 249, Sep. 1990.
Matsumoto Alvin M., “Hormonal Therapy of Male Hypogonadism”Clinical Andrology, vol. 23, No. 4, Dec. 1994.
Munoz-Barroso et al. “Dilation of the Human Immunodeficiency Virus-1 Envelope Glycoprotein Fusion Pore Revealed by the Inhibitory Action of A Synthetic Peptide from gp41”The Journal of Cell Biology, vol. 140, No. 2, 1998, pp. 315-323.
Melikyan et al. “Inner But Not Outer Membrane Leaflets Control The Transition From Glycosylphosphatidylinositol-Anchored Influenza Hemagglutinin-Induced Hemifusion To Full Fusion”The Journal of Cell Biology, vol. 136, No. 5, Mar. 1997, pp. 995-1005.
Steinberger et al. “Effect of Chronic Administration of Testosterone Enanthate of Sperm Production and Plasma Testosterone, Follicle-Stimulating Hormone, and Luteinizing Hormone levels: A Preliminary Evaluation of a Possible Male Contraceptive”Fertility and Sterility, vol. 28, No. 12, 1977.
Sundaram, et al “7α-Methyl-Nortestosterone (MENT): The Optimal Androgen for Male Contraception”,Ann Med25: 199-205, 1993.
Saudek et al., “A Preliminary Trial of the Programmable Implantable Medication System for Insulin Delivery”The New England Journal of Medicine, vol. 321, No. 9, Aug. 1989.
Sefton Michael V. “Implantable Pumps”CRC Critical Reviews in Biomedical Engineering, vol. 14, Issue 3.
World Health Organization “Contraceptive efficacy of testosterone-induced azoospermia and oligzoospermia in normal men”Fertility and Sterility, vol. 65, No. 4, 1996.
Wu et al. “Effects of testosterone enanthate in normal men: experience from a multi-center contraceptive efficacy study”Fertility and Sterilityvol. 65, No. 3, 1996.
Wu F.C. W. “Male Contraception: Current Status and Future Prospects”Clinical Endocrinologyvol. 29, pp. 443-465, 1988.
Zhou et al, “Specificity of Ligand-Dependent Androgen Receptor Stabilization: Receptor Domain Interactions Influence Ligand Dissociation and Receptor Stability”Molecular Endocrinologyvol. 9, No. 2, 1995.
U.S. Appl. No. 09/644,970, filed Aug. 2, 2000, Dalton et al.
C. G. Francisco, et al. “Long-acting contraceptive agents: testosterone esters of unsaturated acids”, Steroids, Jan. 1990, vol. 55, Butterworths.
Carl Djerassi and S.P. Leibo, “A new look at male contraception”, Nature, vol. 370, pp. 11-12.
D. McKillop, et al., “Enantioselective metabolism and pharmacokinetics of Casodex in the male rat”, Xenobiotica, 1995, vol. 25, No. 6, 623-634.
David J. Handelsman, “Bridging the gender gap in contraception: another hurdle cleared” The Medical Journal of Australia, vol. 154, Feb. 18, 1996, pp. 230-233.
David T. Baird and Anna F. Glasier, “Hormonal Contraception - Drug Therapy”, The New England Journal of Medicine, May 27, 1993, pp. 1543-1549.
F.C. W. Wu, “Male Contraception: Current Status and Future Prospects”, Clinical Endocrinology, (1988), 29, pp. 443-465.
Howard Tucker and Glynne J. Chesterson, “Resolution of the Nonsteroidal Antiandrogen -4′- Cyano-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methyl-3′-(trifluoromethyl)-propionanilide and the Determination of the Absolute Configuration of the Active Enantiomer” J. Med Chem. 1988, 31. pp. 885-887.
John M. Hoberman and Charles E. Yesalis, “The History of Synthetic Testosterone”, Scientific American, Feb. 1195, pp. 76-81.
Leonid Kirkovsky, et al., “[125]-Radionated Bicalutamide Analogs as Potential Imaging Agents for Prostate Cancer”, Poster Presentation MEDI 155, 214th ACS National MEeting, Las Vegas, NV, Sep. 7-11, 1997, Department of Pharmaceutical Sciences, University of Tennessee, Memphis, TN 38163.
Leonid Kirkovsky, et al., “Approaches to Irreversible non-steroidal chiral antiandrogens”, Department of Pharmaceutical Sciences, University of Tennessee, 47th Southeast/51st Southwest Joint Regional Meeting of the American Chemical Society, Memphis, TN, Nov. 29- Dec. 1, 1995.
World Health Organisation Task Force on Methods for the Regulation of Male Fertility, “Contraceptive efficacy of testosterone-induced azoospermia in normal men”, The Lancet, vol. 336, Oct. 20, 19
Dalton James T.
Miller Duane D.
Rakov Igor
Cohen Mark S.
Pearl Cohen Zedek Latzer LLP
Seaman D. Margaret
University of Tennessee Research Foundation
LandOfFree
Methylene-bridged selective androgen receptor modulators and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methylene-bridged selective androgen receptor modulators and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methylene-bridged selective androgen receptor modulators and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3867581